Pfizer Inc.

Novo Nordisk A/S

Pharma companies squabble over a promising startup in the market for weight management products

Pfizer sues Novo Nordisk and Metsera - Oninvest

Eli Lilly and Company

Danish Novo Nordisk will release its quarterly report on Nov. 5.

Novo Nordisk's 5 challenges: what's at the center of investment banks' attention 

Novo Nordisk has entered into a battle with Pfizer over Metsera. Why do they want this biotech startup?

Viking Therapeutics, Inc.

Shares of biotech company Viking Therapeutics could triple, according to Canaccord Genuity, which in a <a href="https://www.cnbc.com/2025/10/29/biggest-analyst-calls-wednesday-include-nvidia-apple-tesla-datadog.html">coverage initiation</a> called the firm "one of the leading biotech companies in the obesity drug development space," now <a href="https://oninvest.com/article/gde-investoram-iskat-potencial-nyj-hit-na-rynke-preparatov-ot-lisnego-vesa">dominated</a>&nbsp;by Novo Nordisk and Eli Lilly.

Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside

The retail price of Ozempic, which Trump has called a "weight-loss drug," is about $1,000 for a one-month course

Trump has promised to cut the price of Ozempic to $150. Novo Nordisk and Eli Lilly shares fell

PepsiCo, Inc.

Delta Air Lines, Inc.

Ferrari N.V.

Meta Platforms, Inc.

Apple Inc.

NVIDIA Corporation

Akero Therapeutics, Inc.

Elastic N.V.

Applied Digital Corporation

Apogee Enterprises, Inc.

Levi Strauss & Co.

Clover Health Investments, Corp.

Tilray Brands, Inc.

Helen of Troy Limited

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: stock exchanges wait for a signal from consumers


The maker of Ozempic and Wegovy makes its first major deal under new CEO Mike Doustdar

Liver drugmaker Akero to be acquired by Novo Nordisk; shares soar 17%

The bank doubts that the active ingredient in Ozempic and Wegovy will prove effective in fighting Alzheimer's disease

Morgan Stanley gave one of the worst forecasts for Novo. What could bring down the stock?

Roche Holding AG

AstraZeneca PLC

European pharma giants have a chance to avoid prohibitive duties on branded drugs, says JPMorgan Chase

Pharma stocks in Europe reacted weakly to Trump's threats of new duties

Novo Nordisk's Ozempic has shown to reduce the risk of heart attack, stroke and death in patients with diabetes and cardiovascular disease

Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?

Altimmune, Inc.

Terns Pharmaceuticals, Inc.

Following the meteoric success of Novo Nordisk and Eli Lilly’s semaglutide-based weight-loss injections, the obesity and metabolic disease treatment sector has drawn heightened investor attention. Since Ozempic was <a href="https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html">approved</a>&nbsp;in December 2017, Novo Nordisk’s stock has gained 125%, pushing its <a href="https://companiesmarketcap.com/novo-nordisk/marketcap/">market capitalization</a> to $252 billion. Eli Lilly, after launching <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-Zepboundtm-tirzepatide-chronic-weight">Zepbound</a>&nbsp;in November 2023, has seen its share price climb 23% and its <a href="https://companiesmarketcap.com/eli-lilly/marketcap/">market cap</a> reach $681 billion. Morgan Stanley <a href="https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth#:~:text=Morgan%2520Stanley%2520Research%2520now%2520estimates,about%2520%252415%2520billion%2520in%2520sales">estimates</a>&nbsp;the global market for obesity drugs could exceed $150 billion by 2035.

Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market

While raising the recommendation to "buy", investment bank Berenberg simultaneously lowered the target on Novo securities by 25%